Curcumin is one of the bioactive metabolites of turmeric (Curcuma longa), known for its pleiotropic pharmacological actions, including antioxidant and antiinflammation, anticholinesterase, immunomodulation, and neuroprotection. Substantial evidence suggests the therapeutic benefits of curcumin against neurodegenerative disorders, including Alzheimer's disease (AD), acting on a diverse array of brain targets that make the molecular mechanisms complicated. System biology level-investigation could potentially present a comprehensive molecular mechanism to delineate the neuropharmacological action of curcumin. In this study, we used integrated system pharmacology and molecular simulation analysis to gain insights into the underlying mechanism of curcumin action against AD. Network pharmacology study identified curcumin-targeted potential cellular pathways such as phosphatidylinositol 3kinase/protein kinase B (PI3K/Akt) signaling, neurotrophin signaling, toll-like receptor (TLR) signaling, and autophagy, and proteins such as tropomyosin receptor kinase B (TrkB), liver X-receptor-beta (LXR-β), estrogen receptor-β (ER-β), mammalian target of rapamycin (mTOR), TLR-2, N-methyl-D-acetate receptor subunit 2B (GluN2B), βsecretase and glycogen synthase kinase-3β (GSK-3β), which are intimately associated with neuronal growth and survival, immune response, and inflammation. Moreover, the molecular modeling further verified that curcumin showed a significant binding affinity to mTOR, TrkB, LXR-β, TLR-2, ER-β, GluN2B, β-secretase, and GSK-3β, which are the crucial regulators of molecular and cellular processes associated with AD. Together, the Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted:
Although substantial reports present a wide array of brain targets and propose numerous mechanisms of curcumin action against AD, the information is too diverse to draw a precise conclusion and to identify potential molecular targets. A system biology level study, therefore, needs to be employed to elucidate the precise pharmacological mechanism of curcumin action. Here, we employed an integrated system pharmacology approach, an efficient bioinformatics tool for molecular pharmacology study [15] [16] [17] to identify a potential pharmacological mechanism of curcumin against AD. First, through multiple bioinformatics tools, we demonstrate that curcumin interacted with signaling pathways related to the development and survival of neuron, inflammation and immune response. Next, we employed in silico analysis to further verify the biophysical interaction of curcumin with some potential targets. The present study elucidates the underlying mechanism of molecular neuropharmacology of curcumin and establishes a basis in favor of its therapeutic application against AD.
Results

ADME/T Properties of Curcumin
A diagrammatic overview showing the different steps of network pharmacology was illustrated in Figure 1 . The drug-like properties of curcumin was evaluated by QikProp ADME/T prediction tool. Curcumin exhibited drug-like attributes (Table S1 ) and is more likely to be orally available as it did not violate any of the Lipinski's rule of five [18] (mol_MW < 500, donor HB ≤ 5, and acceptor HB ≤ 10) and Jorgensen's rule of three [19] (QPlogS > −5.7 and QPPCaco > 22 nm/s). Moreover, the predicted brain/blood partition coefficient (QPlogBB) of curcumin was −2.256, which falls within the recommended range (−3.0-1.2), indicating that this polyphenolic might pass the blood-brain barrier. Figure 1 . A diagrammatic overview of the system pharmacology-based elucidation of neuropharmacological action mechanism of curcumin in AD therapy.
Target Fishing
A total of 238 targets of curcumin were retrieved from the PALM-IST database (Table   S2 ) and validated through literature scanning in the PubMed database. Targets that have been reported to be under the regulation of curcumin in AD-associated experimental evidence were primarily considered.
Network Building
Curcumin-Target-Target-AD (C-T-T-AD) network presented the interactions among the curcumin's targets. A total of 222 targets were associated with AD ( Figure 2 ). The highly connected targets include those that are the members of crucial cellular pathways such as PI3K/AKT pathway (AKT1, PIK3CA), MAPK pathway (MAPK1, MAPK3, MAPK8), growth factor pathway (BDNF, NTRK2, EGF, VEGFA, EGFR, NGF), and toll-like receptor pathway (TLR2), indicating the involvement of these targets or others to their upstream signaling as a potential drug-target for curcumin in the AD treatment. Moreover, some 5 of 27 other AD-associated potential targets, including LXR-β (NR1H2), ER-β (ESR1), mTOR, βsecretase (BACE1), and AChE have appeared. Small circular nodes represent targets of curcumin. Node size is proportional to its degree. Edges represent interaction among curcumin, targets, and AD.
Gene Ontology (GO) Analysis
Top 10 highly enriched GO terms under biological process (BP), molecular function (MF), and cellular component (CC) were displayed ( Figure 3A ). The CC term with the highest gene sequestration was the cytosol (103), followed by the plasma membrane (101).
The highly enriched MF term was protein binding (182). The overrepresented biological processes include transcription regulation, inflammatory response, lipopolysaccharidemediated signaling pathway, MAPK cascade, and cellular response to hypoxia, which are closely associated with the AD pathobiology. Moreover, the target proteins were categorized into 21 different classes based on their cellular function, indicating their functional diversity ( Figure 3B ). Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 January 2020 doi:10.20944/preprints202001.0109.v1
Network and Pathways related to AD Pathophysiology
A comprehensive network visualizes the interactions of curcumin's targets with AD and AD-associated cellular pathways, which were categorized into ten modular systems using KEGG pathway annotation ( Figure 4 ). A total of 18 signaling pathways were enriched (p-value < 0.01) in the "signal transduction" module ( Figure 5A ). Most overrepresented signal transduction pathways include PI3K/Akt signaling ( Figure 5B ) and
MAPK signaling, which are involved in neuronal growth and survival. TrkB, a curcumin targeted protein, regulates the enriched signaling pathways involved in neuronal growth and survival. Therefore, the interaction of curcumin with TrkB was further verified by in silico analysis. Small red nodes represent potential druggable targets.
Enriched nervous system-related pathways ( Figure 6A ) include neurotrophin signaling ( Figure 6B ), dopaminergic synapse and long-term potentiation, whose functional impairment is associated with AD pathobiology. Several inflammation-related signaling pathways, including NF-κB signaling and TNF signaling, were also enriched ( Figure S1 ).
LXR-β, a curcumin targeted proteins involved in the regulation of the enriched 8 of 27
inflammatory pathways, was further verified for its physical interaction with curcumin by in silico analysis. In addition, numerous immune system pathways ( Figure 7A ), including toll-like receptor signaling ( Figure 7B ), as the top enriched pathway, appeared in the network. Considering the significance of TLR signaling and the involvement of TLR2 in the immune signal recognition, the interaction of curcumin with this receptor target was further validated through molecular docking. Cellular pathways under transport and catabolism include autophagy and mitophagy which are crucially implicated in AD. Several proteins of these cellular pathways were targeted by curcumin ( Figure 8 ). Two curcumin-targeted proteins, such as mTOR, a central regulator of autophagy, and estrogen receptor-β, a nuclear receptor regulating mitophagy, were further validated for their interactions with curcumin by molecular modeling. CASP9, CASP8, CASP12, Fas and CaM) ( Figure 9 ). Of these, the interaction of BACE and AChE with curcumin were further validated through molecular simulation as these enzymes are already potential drug targets for AD. Figure 9 . AD pathway in KEGG mapper linked many of the curcumin targets that are highlighted in red.
Molecular Docking Simulation
Following the network analysis, molecular docking analysis was further incorporated to validate the binding of curcumin to LXR-β, ER-β, TrkB, TLR2, mTOR, BACE1, AChE, GSK-3β and GluN2B, which are crucial regulators of several AD-related molecular and cellular processes. The docking analysis revealed that curcumin interacted with all targets with binding energy, ranging from -39 to -62 kcal/mol, respectively (Table S3 ). Among these targets, curcumin showed the highest binding energy to mTOR, while the lowest was obtained for BACE-1. The significant binding was also found for LXR-β, AChE, GSK3β, 
Discussion
In this study, we elucidated the molecular mechanism of neuropharmacological action of curcumin against AD using integrated system pharmacology and molecular simulation approach. Initially, we characterized the pharmacokinetic behaviors of curcumin, which supports its drug-like properties and accessibility to the brain tissue. However, numerous studies claimed the poor bioavailability that limits the use of curcumin through oral administration. To overcome this limitation, nanoparticle-mediated drug delivery systems have been proposed for curcumin [20] .
Gene ontology-based bioinformatics analysis identified several enriched biological processes, including inflammatory response, MAPK cascade, response to hypoxia, and LPS-mediated signaling, that are linked with the AD pathology, suggesting the possibility that curcumin could intervene the disease progression through modulating these vital biological processes. The system pharmacology information, as revealed from network analysis, indicated that curcumin exhibited interaction with the target proteins of many crucial pathways at the molecular and cellular levels.
In the pathway analysis, signal transduction pathways are predominantly targeted by curcumin. Of these, the PI3K/Akt signaling pathway, along with the MAPK pathway, regulates neuronal growth and survival. Curcumin showed interaction with multiple downstream effectors of these pathways, notably GSK-β and mTOR. Being a broad spectrum phosphorylating enzyme, GSK-β once activated catalyzes the phosphorylation of many substrates, including Tau. Aberrant activation of GSK-3β results in Tau hyperphosphorylation that leads to tangle formation within the neurons [21] . The interaction and binding affinity of curcumin with GSK-3β in this network pharmacology and molecular docking analysis and its inhibition against GSK-3β activity in the previous reports [22] suggest that curcumin could help stabilize Tau-linked microtubules.
The nervous system-related pathways-particularly neurotrophin signaling-are crucial for the maintenance of adult neurons and are closely associated with AD pathobiology. In AD, TrkB signaling, the most dominant neurotrophin signaling pathway in the adult brain, is severely interrupted, primarily due to the insufficient neurotrophic (particularly BDNF) support that causes atrophy and death of the neurons and could aggravate AD pathogenesis [23, 24] . However, pharmacological intervention by BDNF mimetic could help the compromised BDNF/TrkB signaling regain its physiological function. Substantial evidence suggests that curcumin either enhances or restores the BDNF level in the brain [25] [26] [27] and shows neuroprotective function through activating BDNF/TrkB-dependent MAPK and PI3K/Akt cascades [28, 29] . In line with these evidence, our system pharmacology and molecular docking analysis also revealed that curcumin showed an interaction and a significant binding affinity to TrkB, which suggests that curcumin could function as BDNF-mimetic and modulate neuronal growth and survival through modulating the classical neurotrophin/PI3K/Akt signaling pathway.
Curcumin also showed interaction with multiple synaptic proteins that are often deregulated in AD. For example, the activity of GluN2B, an extrasynaptic glutamate receptor, is critically implicated in the development of AD, whereas GuN2A is clearly involved in the memory. The effect of curcumin on the latter has been well-established [30] ;
however, the interaction of curcumin with GluN2B might be either agonistic or antagonistic, which is needed to be investigated using a suitable experimental model. Our in silico findings, however, indicated a significant interaction between curcumin and GluN2B.
Another curcumin-targeted synaptic protein was AChE that is involved in cholinergic neurotransmission. The cholinergic deficit, one of the pathological consequences in AD, is the primary target of current AD therapy and could be compensated by the AChE inhibitor.
Previously reported anticholinesterase activity [31] and our molecular docking results suggest that curcumin might be an alternative to the current anti-AChE agent.
Curcumin's interaction with several proteins of inflammation-related pathways, particularly TNF and NF-κB signaling pathways, suggest that curcumin-mediated antiinflammatory action could play a significant role in the treatment of AD. Activation of NF-κB pathway triggers inflammation by inducing the release of proinflammatory and inflammatory components like TNF, COX-2, iNOS, IL-1, IL-6 [11] . Deregulation of NF-κB signaling pathway in immune cells induces a detrimental inflammatory response to the neuron, which leads to neuronal death. Evidence suggests that curcumin can alleviate neurodegeneration and neuroinflammation through multiple mechanisms, by reducing inflammatory mediators such as TNF-α, IL-1β, and NF-κB gene expression [32] Given the key role of cholesterol in brain physiology and function, disturbances in cholesterol homeostasis provoked inflammation and oxidative stress, and thus, have been associated with the onset of AD [33] . LXRs, particularly LXR-β, play a critical role in brain cholesterol homeostasis. Upon ligand activation, LXR-β upregulates the expression of ApoE, ABCA1, and ABCG1, the key genes in reverse cholesterol transport [34] . The activity of ABC transporters mediates the cholesterol efflux to ApoE, which enhances Aβ clearance to blood [34, 35] . An LXR-β dependent expression of ABCA1 and ABCG1 by curcumin has been reported [36] . These findings suggest that curcumin might take part in LXR-βmediated cholesterol homeostasis in the brain. Moreover, curcumin showed a significant binding affinity to LXR-β in our docking analysis, indicating that this natural molecule could be a potential LXR-β agonist, which might play a significant role against AD pathology through maintaining cholesterol homeostasis and Aβ clearance involving ABCdependent pathways.
Several immune-related pathways that are intimately associated with AD progression are targeted by curcumin. For instance, toll-like receptor (TLR) signaling is crucially implicated in innate immunity. TLR2, a pattern recognition receptor that senses both endogenous and exogenous antigens, produces an immune response in the cells [37] . The current network pharmacology and in silico findings on curcumin-TLR2 interaction and previously reported curcumin-mediated TLR2-downregulation [38] suggest that curcumin could improve inflammation-mediated AD pathobiology through regulating TLR-mediated immune response.
Autophagy is a lysosome-dependent degradation pathway that plays a crucial role in cell survival and homeostasis. The impairment of this surveillance pathway is known to be associated with AD pathogenesis. Inhibition mTOR, a critical regulator of autophagy restores autophagic flow that attenuates neurodegeneration [39] . mTOR inhibitor might, therefore, be a potential therapeutics in AD. Wang and colleagues reported that curcumin induces autophagy by inhibiting PI3K/Akt/mTOR signaling pathway in APP/PS1double transgenic mice [40] . In addition, curcumin might also take part in autophagy regulation through interaction with estrogen receptor-β (ER-β) as it has shown to stimulate transcription of estrogen-responsive genes [41] . Also, it has been established that ER-β induces autophagy via suppressing the PI3K/AKT/mTOR pathway [42] . On the other hand, mitophagy, mitochondria-targeted autophagy that clears abnormal mitochondria, regulates the mitochondrial quality and promotes cell survival in neurodegenerative diseases [43] could represent an attractive drug target for AD therapy. In our network pharmacology analysis, curcumin targeted several molecular markers of both autophagy and mitophagy.
Of these, mTOR is of particular interest, showing the highest binding affinity to curcumin in molecular docking analysis. The binding affinity of curcumin to ER-β is also significant.
Together, these evidence suggest that curcumin could contribute potential pharmacological benefits in AD patients through modulating autophagy.
Amyloid β deposition in the brain installs AD pathogenesis [44] . β-Secretase, an enzyme that initiates Aβ formation in the brain [45] , therefore, offers an attractive target for an anti-AD agent. Curcumin has been reported to inhibit β-Secretase activity [46] .
Moreover, curcumin has been shown to inhibit the formation of Aβ and reduce the same in an animal model [12] . The present system pharmacology and in silico analysis further support the interaction of curcumin with β-Secretase and suggest that curcumin might offer a promising therapeutic lead against AD.
Materials and Methods
ADME/T Analysis of Curcumin
Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion/transport (ADME/T) of curcumin were analyzed through QikProp (Schrödinger Release 2019-3: QikProp, Schrödinger, LLC, New York, NY, USA), an ADME/T prediction tool. ADME/T properties forecast the drug-like activity of ligand molecules during clinical trials based on Lipinski's rule of five.
Data Mining for Target Selection
First, we collected relevant targets information against every selected compound primarily from 'Pathway Assembly from Literature Mining-an Information Search Tool'
(PALM-IST) (www.hpppi.iicb.res.in/ctm) [47] . We then cross-checked every target protein on an individual basis using PubMed database links and excluded those targets that had no direct interaction with the curcumin. Additionally, while scanning the PubMed database, we included some curcumin targets that we skipped. A similar approach of target fishing has been employed in our recently published article [48] which identifies real-time targets because the proteins which are under the direct regulation (up or down) of a particular compound are the actual targets and are implicated in the concerned biological effects in experimental models. Finally, we selected only those targets, for further analysis, which were coincided with AD-related genes from DisGeNET database v6.0 (Barcelona, Spain) [49] , a database that integrates human gene-disease associations from expert-curated databases and text-mining derived associations. UniProt (http://www.uniprot.org/), a database of protein sequence and functional information, was searched to retrieve the protein information, including protein name, gene ID, and host organism [50] .
Network Construction for Curcumin-Target-Target-Alzheimer's Disease (C-T-T-AD)
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), an online tool for functional protein association networks, was used to construct the protein-protein interaction (PPI) network among the targets. The curcumin-target and PPI networks were combined through Cytoscape v3.7.1 (Seattle, Washington, USA) [51] to construct the curcumin-target-target network, which was finally merged with the target-AD network to establish C-T-T-AD network by Cytoscape.
Gene Ontology (GO) Analysis
Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8. was used to perform the functional enrichment analysis of GO for the biological process, molecular function, and cellular components [52] (https://david.ncifcrf.gov/). GO terms were considered as significant at p-value < 0.05. Target proteins were categorized by the Panther classification system [53] (http://pantherdb.org/).
Network and Pathway Analysis
To extensively understand the molecular mechanisms, NetworkAnalyst, a visual analytics platform for comprehensive gene expression profiling & meta-analysis, was used to construct a comprehensive network [54] (https://www.genome.jp/kegg/tool/map_pathway2.html).
Molecular Docking and Binding Energy Analysis
The three dimensional crystal structure of human LXR-β (PDB ID: 1P8D), ER-β (PDB ID: 1QKM), TrkB (PDB ID: 1HCF), TLR2 (PDB ID: 6NIG), mTOR (PDB ID: 5GPG), BACE1 (PDB ID: 5HDZ), AChE (PDB ID: 4EY7), GSK-3β (PDB ID: 4AFJ), GluN2B
(PDB ID: 5EWM) were retrieved from the protein data bank [56] and prepared for molecular docking studies by using protein preparation module of Schrödinger 2017-1
following previously described protocols [57] [58] [59] [60] [61] . Briefly, the amino acid orientation in the PDB file was fixed by correcting bond orders, adding charges and hydrogen. Following that the structure was optimized at neutral pH (7.0 ± 2.0), and then minimized by using OPLS 3 force filed limiting maximum heavy atom RMSD to 0.30 Å. The candidate compounds structures were prepared for molecular docking by minimizing with OPLS 3 force field composed of the non-polar solvent accessible surface area and van der Waals interactions [62] . Here, as the source in Prime MM-GBSA simulation, the glide pose viewer file of the best conformation was given. For modeling directionality of hydrogen-bond and π-stacking interactions, the dielectric solvent model VSGB 2.0 [63] was used to apply empirical corrections. Keeping the protein chain flexible [64] [65] [66] [67] [68] , minimizing approach is applied as sampling methods. The analysis denotes more excellent binding by more negative binding energy. Overall free energy of binding:
ΔG bind = G complex -(G protein + G ligand ), where G = EMM + GSGB + GNP
Conclusion
The present system pharmacology-based investigation revealed that the PI3K/Akt signaling, neurotrophin signaling, toll-like receptor signaling, and autophagy are the major cellular signaling pathways that are primary targets of curcumin. In addition, TrkB, LXR-β, mTOR, TLR-2, and β-secretase are the potential druggable targets that could be exploited for future curcumin-based drug designing against AD pathology. Together, our system pharmacology and computational findings, along with the previously described experimental evidence, provide clear insights into the underlying molecular mechanism of neuroprotection of curcumin against AD.
Supplementary Materials: Figure S1 : Inflammatory pathways enriched in network analysis, Table S1 : ADME/T properties of curcumin, Table S2 : Data for the curcumin targets used to construct C-T-T-AD network and disease-target-pathway network, Table   S3 : Molecular docking simulation findings of curcumin targets. 
